Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
NCT01603992 · View on ClinicalTrials.gov ↗
Study Summary
Background: \- Marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment ( spontaneous quitting). Studies have suggested that there are some common strategies that many individuals use in spontaneous quitting, such as changing one s lifestyle or identity, reminding oneself of negative consequences, support from family and friends, and religion. However, more research is needed to determine potential treatment strategies for marijuana use. Objectives: * To identify strategies used to help with marijuana quitting among non-treatment seeking adult marijuana users. * To identify withdrawal symptoms experienced during marijuana quitting and their relationship to the quitting strategies used and the outcome of the quit attempt. * To evaluate whether subgroups of marijuana users differ in their experience of marijuana quitting. Eligibility: \- Individuals at least 18 years of age who have made at least one attempt to quit marijuana use. Design: * The study will consist of one visit of approximately 1 to 2 hours. * Participants will fill out three questionnaires. The questionnaires have different types of questions, and will ask about background and lifestyle, marijuana use and craving patterns and behaviors, and difficulties in previous attempts to quit using marijuana.
Conditions Studied
Study Locations (3)
Maryland
- National Institute on Drug Abuse, Biomedical Research Center (BRC) — Baltimore
- Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue — Catonsville
South Carolina
- Medical University of S. Carolina — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2005-11-08 |
| Est. Completion | 2012-05-03 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603992
The ClinicalTrials.gov registry entry for NCT01603992 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 822 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 108 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Cannabis Dependence appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01603992 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Maryland, South Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01603992 about?
NCT01603992 is a clinical study titled "Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms". Background: \- Marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment ( spontaneous quitting). Studies have suggested that there are some common strategies that many individuals use in spontaneous quitting, su...
What is the current status of trial NCT01603992?
This trial is currently completed. The enrollment target is 822 participants. The study started on 2005-11-08. Estimated completion is 2012-05-03.
What conditions does trial NCT01603992 study?
This clinical trial studies the following conditions: Cannabis Dependence, Cannabis Abuse. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01603992?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 108 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01603992 being conducted?
This trial has 3 study locations across Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.